Tags : Mycenax

Insights+ Key Biosimilars Events of May 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference […]Read More

Mycenax Signs an Agreement with Gedeon Richter for LusiNEX

Shots: Mycenax to sell LusiNEX project, including cell banks, CMC technology, intellectual properties, and clinical trial results to Gedeon Richter making a total deal value $16.5M. Mycenax to get payments as it completes the stages of asset transfer which will be utilized to operation and facility expansion which further strengthen Mycenax’s capacities in CDMO business […]Read More

Gedeon Richter Signs an Asset Purchase Agreement with Mycenax for

Shots: Mycenax to get $5M upfront and will get $16.5M as total deal value in four installments. Richter to get exclusive WW rights to develop, manufacture and commercialize biosimilar tocilizumab The focus of the agreement is to bolster its rheumatology portfolio with addition of Mycenax’s candidate. The biosimilar tocilizumab assets comprise the cell lines, intellectual […]Read More